In Vitro Activities of Three New Dihydrofolate Reductase Inhibitors against Clinical Isolates of Gram-Positive Bacteria▿
AUTOR(ES)
Bowker, Karen E.
FONTE
American Society for Microbiology (ASM)
RESUMO
BAL0030543, BAL0030544, and BAL0030545 are dihydrophthalazine inhibitors with in vitro potency against gram-positive pathogens. The MIC50s for methicillin (meticillin)-sensitive Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, hetero-vancomycin-resistant Staphylococcus aureus, and vancomycin-resistant Staphylococcus aureus (VISA) range from 0.015 to 0.25 μg/ml (MIC90s ≤ 0.5 μg/ml). MIC50s for beta-hemolytic streptococci range from 0.03 to 0.06 μg/ml, MIC50s for Streptococcus pneumoniae range from 0.06 to 0.12 μg/ml, MIC50s for Listeria monocytogenes range from 0.015 to 0.06 μg/ml, and MIC50s for Streptococcus mitis are ≤0.015 μg/ml. These three dihydrophthalazine antifolates have improved potency compared to that of trimethoprim and activity against gram-positive pathogens resistant to other drug classes.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2772311Documentos Relacionados
- In vitro activities of two glycylcyclines against gram-positive bacteria.
- In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria.
- In Vitro Activities of Peptide Deformylase Inhibitors against Gram-Positive Pathogens
- In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.
- In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive Bacteria
